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Abstract
Background: This study evaluated the prescribing trends of four
commonly prescribed strong opioids in primary care and explored
utilization in non-cancer and cancer users.
Methods: This cross-sectional study was conducted from 2000 to 2010
using the UK Clinical Practice Research Datalink. Prescriptions of
buprenorphine, fentanyl, morphine and oxycodone issued to adult
patients were included in this study. Opioid prescriptions issued after
patients had cancer medical codes were defined as cancer-related use;
otherwise, they were considered non-cancer use. Annual number of
prescriptions and patients, defined daily dose (DDD/1000 inhabitants/day)
and oral morphine equivalent (OMEQ) dose were measured in repeat
cross-sectional estimates.
Results: In total, there were 2,672,022 prescriptions (87.8% for
non-cancer) of strong opioids for 178,692 users (59.9% female, 83.9%
non-cancer, mean age 67.1 ± 17.0 years) during the study period. The
mean annual (DDD/1000 inhabitants/day) was higher in the non-cancer
group than in the cancer group for all four opioids; morphine (0.73 ± 0.28
vs. 0.12 ± 0.04), fentanyl (0.46 ± 0.29 vs. 0.06 ± 0.24), oxycodone
(0.24 ± 0.19 vs. 0.038 ± 0.028) and buprenorphine (0.23 ± 0.15 vs.
0.008 ± 0.006). The highest proportion of patients were prescribed low
opioid doses (OMEQ ≤ 50 mg/day) in both non-cancer (50.3%) and
cancer (39.9%) groups, followed by the dose ranks of 51–100 mg/day
(26.2% vs. 28.7%), 101–200 mg/day (15.1% vs. 19.2%) and >200 mg/day
(8.25% vs. 12.1%).
Conclusions: There has been a huge increase in strong opioid prescribing
in the United Kingdom, with the majority of prescriptions for non-cancer
pain. Morphine was the most frequently prescribed, but the utilization of
oxycodone, buprenorphine and fentanyl increased markedly over time.
1. Introduction
Opioid analgesics have long been used as the gold
standard to treat severe pain, most notably for acute
pain and in palliative care. The use of opioids in
chronic non-cancer pain (CNCP) has been much
more controversial. Research from the United States
(Zerzan et al., 2006; Sullivan et al., 2008), Australia
(Leong et al., 2009), Canada (Fischer et al., 2011)
and some European countries (Fredheim et al., 2010)
have shown a significant increase in opioid utilization
in the past decade, predominantly for patients with
CNCP (Caudill-Slosberg et al., 2004; Gilson et al.,
2004).
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It is estimated that 90–95% of long-term opioid
therapy is prescribed for non-cancer pain conditions
and approximately 3% of the US population with
non-cancer pain used opioids regularly for a month or
more per year (Sullivan and Ferrell, 2005). However,
there is a lack of robust evidence supporting the long-
term opioid use in CNCP (Chapman et al., 2010), as
the majority of the randomized controlled trials are of
short duration (Chou et al., 2003, 2009; Noble et al.,
2010). In addition, population-based research on the
extent and characteristics of exposure to long-term
opioids are also limited (Sullivan et al., 2008; Trescot
et al., 2008).
A variety of opioids are available on the market with
different clinical potencies, which can be roughly esti-
mated by an equianalgesic ratio table (Gordon et al.,
1999). The World Health Organization (WHO) consid-
ers a country’s opioid consumption as an indicator of
progress in pain relief, especially for cancer pain
(Scholten et al., 2007). Single- or cross-nation studies
have reported both under- (Ponizovsky et al., 2012)
and over- (Clausen, 1997) opioid utilization. Although
increasing opioid prescribing for non-cancer patients
may imply better attention to managing unresolved
pain (Portenoy, 2004), widespread use of long-term
opioids in CNCP has raised safety concerns. Recent
studies suggest that long-term opioid use is associated
with more frequent emergency department atten-
dances and an increased incidence of side effects
(Okie, 2010) and risk of opioid diversion and abuse,
overdose and deaths (Gilson et al., 2007).
For patients receiving long-term opioid therapy
for CNCP, opioid-related overdose death was found to
be associated with higher prescribed doses (Bohnert
et al., 2011). Specifically, the risk of drug-related
adverse events was higher among patients prescribed
doses greater than morphine 50 mg/day. Compared
with patients receiving morphine 1–20 mg/day,
patients receiving 50–99 mg/day or above 100 mg/day
had a 3.7- and 8.9-fold increase in overdose risk,
respectively (Dunn et al., 2010).
The aggregated dispensing data reported by the UK
National Health Service (NHS) Information Centre
suggests a large increase in opioid prescribing in the
past decade (National Health Service. National
Treatment Agency for Substance Misuse, 2011). It is
likely that this increase is predominantly associated
with CNCP. However, there is limited information on
opioid prescribing patterns in CNCP and cancer pain
in the United Kingdom. This study aimed to describe
the trends of the most commonly prescribed strong
opioids (buprenorphine, fentanyl, morphine and oxy-
codone) in a UK primary care setting from 2000 to
2010 stratified by cancer and non-cancer groups.
2. Methods
2.1 Study design and data source
This retrospective, cross-sectional study was conducted from
2000 to 2010 using the Clinical Practice Research Datalink
(CPRD) after being granted approval from the Independent
Scientific Advisory Committee of the Medicines and Health-
care Products Regulatory Agency for Database Research.
CPRD is a longitudinal computerized database containing 5.2
million active patients’ anonymous medical records collected
from approximately 636 primary care practices in the United
Kingdom (Williams et al., 2012).
Prescriptions for four strong opioid (morphine and oxyco-
done, buprenorphine and fentanyl) issued during 2000–2010
were identified from CPRD by specific drug-related product
codes. The four strong opioids are commonly prescribed for
chronic pain management compared with other strong
opioids (hydromorphone, meptazinol, pethidine) available in
the United Kingdom. Injection and suppository prescriptions
(3.1%) were excluded from this study. In addition, prescrip-
tions for buprenorphine sublingual tablets 2 and 8 mg, which
are almost exclusively used for managing opioid dependence
instead of pain, were not included either. All selected opioid
prescriptions were linked to the individual patient’s data file
to extract demographic and diagnosis information. Adult
users of strong opioids (aged 18–107 years old) with identifi-
able gender were included in this study. Prescriptions for the
included patients were recorded for analysis up to 107 years
old (the oldest age of patients registered in the CPRD data-
base). The included strong opioid users were further stratified
What’s already known about this topic?
• Studies in the United States regularly report
increased opioid utilization and associated
increased dose-related risks of dependence,
misuse and mortality, but little is known in the
United Kingdom.
What does this study add?
• Similar to the United States and some European
countries, this study found an enormous increase
in strong opioid prescribing in UK primary care,
most commonly for non-cancer indications.
• Although most patients were prescribed low
doses, the utilization of newer opioids increased,
although the daily morphine equivalent dose
remained the same.
• Further analysis of large patient databases will
determine whether the harms associated with
opioids are similar to those reported in the North
America.
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into cancer and non-cancer groups using specific medical
codes for related cancer diagnosis.
Each prescription record contains information of item
name and strength, prescription date, quantity and numeri-
cal daily dose (NDD). The NDD is a built-in information in
CPRD that is transformed from the text records of adminis-
trative instructions. Less than 0.2% of prescriptions with
quantity missing or extreme values (i.e., greater than two
times of the 99th percentile value for quantity or day supply)
were excluded from the analysis. The NDDs for prescriptions
recorded as ‘as directed’ or ‘as required’ were identified as
missing values (35.7%) and were replaced by the recom-
mended number of daily dose from the British National
Formulary according to an expert’s opinion.
2.2 Utilization measures
Utilization measures for the four opioids included annual
number of prescriptions, number of patients, defined daily
dose (DDD) for each opioid and oral morphine equivalent
(OMEQ) dose per patient per day, and these measures were
calculated in repeat cross-sectional estimates for each year
and further stratified into cancer and non-cancer groups.
2.3 Number of prescriptions and users
The number of prescriptions and the number of prescriptions
per patient in cancer and non-cancer groups were calculated
annually. The number of patients prescribed strong opioid
was repeatedly calculated by each calendar year, and patient
and corresponding strong opioid prescriptions were catego-
rized as either ‘cancer’ group after the first cancer diagnosis
recorded; otherwise, they were included in the ‘non-cancer’
group. Patients’ demographic data (age and gender) were
also recorded. Age was calculated based upon the date of the
first prescription included in the study and stratified into five
groups (i.e., ≤40, 41–50, 51–65, 66–80 and >80 years old).
2.4 Deﬁned daily dose
The quantity of each prescription was multiplied by the
strength (in milligrams) of the prescription to calculate the
amount of each prescription. For transdermal buprenor-
phine and fentanyl formulations, the strength per hour and
the duration of delivery rate of the formulation were con-
sidered in the dose calculation.
The annual total prescribed dose of each opioid entity was
divided by the DDD (the daily average maintenance for a
70-kg male patient) of the particular opioid (Zerzan et al.,
2006; Hamunen et al., 2008), as defined by the WHO Col-
laborating Centre for Drug Statistics based upon the Ana-
tomical Therapeutic Chemical classification system (WHO
Collaborating Centre for Drug Statistics Methodology, 2013).
The result was then divided by the total number of patients
registered in the CPRD for the year, and then multiplied by
1000 and further divided by 365 to derive the annual
number of DDDs per 1000 inhabitants per day, which was
used as an indicator for the prevalence of strong opioid
utilization.
2.5 Oral morphine equivalent dose
The dose for each prescription was multiplied by the equi-
analgesic ratio of the opioid (Mercadante et al., 2007;
Sullivan et al., 2008; Svendsen et al., 2011) to derive the
OMEQ dose. The number of ‘days of supply’ for each pre-
scription was calculated by dividing the quantity by the NDD.
Total days of supply of prescriptions for each patient per
calendar year were calculated and the overlapping days of
supply between prescriptions within a year were subtracted.
Annual OMEQ dose per day of supply was calculated by
dividing the total OMEQ dose by the total days of supply for
each patient in a calendar year. The annual number of users
was further stratified by the four daily OMEQ dose ranks,
including ≤50 (low dose rank), 51–100, 101–200 and
>200 mg/day (higher dose ranks). The contribution of each
of the four opioids to each OMEQ dose rank was calculated.
2.6 Data analysis
Descriptive statistics were used to report outcome variables
for each year, including number of strong opioids users,
number of opioid prescriptions, number of prescriptions per
patient and opioid dose per day. Linear trend analysis was
conducted on annual outcome measures and the percentage
change between 2000 and 2010 data for each variable was
also reported. Sensitivity analyses were conducted to explore
the impacts of NDD missing data management on the dose
calculation. All analyses were conducted using Stata 12
(Stata Corp LP, College Station, TX, USA, 2011).
3. Results
3.1 Number of strong opioid users
In total, 2,672,022 prescriptions of the four strong
opioid analgesics were prescribed for 178,692 users
(59.9% female) during the 11-year study period
(Table 1). The mean age of strong opioid users was
67.1 ± 17.0 years (mode: 77; range: 18–107 years). Of
the five age ranks, there was a higher proportion of
patients aged 66–80 years old (33.6%), followed by
aged more than 80 (24.4%) and 51–65 years old
(23.8%). The number of strong opioid users each year
increased over time from 9479 to 53,666 (466.2%
increase) during the study period, and this represents
1.8–9.2 per thousand patients that were registered in
CPRD.
Of all strong opioid users, 28,796 (16.1%) users had
cancer diagnoses recorded during the study period and
any subsequent prescriptions were categorized as the
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‘cancer group’, and the remaining 149,896 (83.9%)
patients without a cancer diagnosis were categorized
as the ‘non-cancer group’. There was a higher propor-
tion of female patients in the non-cancer group
(62.4%) than the cancer group (47.1%). The total
increase in the annual number of female strong opioid
users (537.7%) was higher than that of male users
(372.6%), and similarly, a higher increase of female
users was found in both non-cancer (575.3% vs.
414.3%) and cancer groups (300.0% vs. 216.7%).
The mean age of strong opioid users was slightly
lower in the non-cancer group (66.6 ± 17.6; mode:
80; range: 18–107 years) than the cancer group
(69.7 ± 12.9; mode: 74; range: 18–106 years). In the
non-cancer group, there was a slightly larger propor-
tional increase in the number of patients in the young-
est (<40 years) and oldest (>80 years) compared with
other age groups over the study period.
3.2 Number of prescriptions
Prescriptions for the four strong opioids (n =
2,672,022) accounted for 94.7% of the total number
of strong opioid prescriptions identified during study
period, and a majority (n = 2,347,282; 87.8%) of those
strong opioid prescriptions were issued without or
prior to a cancer diagnosis record and categorized as
the non-cancer group; only 12.1% prescriptions
(n = 324,740) were issued with or following to a
cancer diagnosis.
For all patients, the total number of prescriptions
per patient increased overtime from 5.7 in 2000 to 9.4
in 2010 (64.7%). The mean number of prescriptions
issued per patient per year was slightly higher in the
non-cancer group (from 6.0 in 2000 to 9.5 in 2010)
than in the cancer group (from 4.6 to 8.8) during the
study period. However, the increase in the annual
number of prescriptions per patient in non-cancer
group (59.6 %) was lower than in the cancer group
(91.2%) (Fig. 1).
Of the four strong opioids, morphine was the most
frequently prescribed opioid, with the highest propor-
tion in total number of prescriptions in both the
non-cancer (47.3%) and the cancer groups (61.4%),
followed by buprenorphine (18.6% vs. 4.7%), fenta-
nyl (18.4% vs. 17.0%) and oxycodone (15.5% vs.
16.7%) (Fig. 2). However, the greatest increase in
annual number of prescriptions was for oxycodone in
both the non-cancer (11,265.5%, from 764 to 86,833)
and cancer groups (8939.5%, from 124 to 11,209),
followed by buprenorphine (1650.6% vs. 4865.4%),
fentanyl (1283.5% vs.765.0%) and morphine
(422.3% vs. 324.6%).
Table 1 Characteristics of strong opioid users included during study period.
Total opioid users Non-cancer group Cancer group
Number of patients 178,692 (100%) 149,896 (83.9%) 28,796 (16.1%)
Gender
Male 71,638 (40.1%) 56,392 (37.6%) 15,246 (52.9%)
Female 107,054 (59.9) 93,504 (62.4) 13,550 (47.1%)
Age (years)
Mean ± SD (range) 67.1 ± 17.0 (18–107) 66.6 ± 17.6 (18–107) 69.7 ± 12.9 (18–106)
Mode 77 80 74
Rank of age
≤40 14,928 (8.4%) 14,318 (9.6%) 610 (2.1%)
41–50 17,625 (9.9%) 15,937 (10.6%) 1,688 (5.9%)
51–65 42,521 (23.8%) 34,746 (23.2%) 7,775 (27.0%)
66–80 60,091 (33.6%) 47,464 (31.7%) 12,627 (43.9%)
>80 43,527 (24.4%) 37,431 (25.0%) 6,096 (21.2%)
SD, standard deviation.
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Figure 1 Number of strong opioid prescriptions and users in non-cancer
and cancer groups.
Strong opioid prescribing in the United Kingdom C.S. Zin et al.
© 2014 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of
European Pain Federation - EFIC®
1346 Eur J Pain 18 (2014) 1343–1351
3.3 Deﬁned daily dose
Of all four strong opioids, morphine had the highest
mean annual DDD (0.85 ± 0.33 per 1000 inhabitants
per day) during the study period, followed by fentanyl
(0.52 ± 0.32), oxycodone (0.28 ± 0.21) and buprenor-
phine (0.24 ± 0.16). The mean annual DDD (per 1000
inhabitants per day) was higher in the non-cancer
group than in the cancer group for all four strong
opioids, that is, morphine (0.73 ± 0.28 vs. 0.12 ± 0.04),
fentanyl (0.46 ± 0.29 vs. 0.06 ± 0.24), oxycodone
(0.24 ± 0.19 vs. 0.038 ± 0.028) and buprenorphine
(0.23 ± 0.15 vs. 0.008 ± 0.006).
The increase in annual DDD (per 1000 inhabitants
per day) in both non-cancer and cancer groups was
similar to the number of prescriptions of the four
strong opioids, in which oxycodone had the highest
compared to buprenorphine, fentanyl and morphine
(Fig. 3).
3.4 Annual days of supply
The mean annual days of supply per patient during the
study period were 124.9 ± 121.6 days, and this was
longer for patients in the non-cancer group
(130.6 ± 124.2 days) than in the cancer group
(88.9 ± 95.8 days). There was an increase in the mean
annual days of supply per patient over the study
period (56.9%), but this was higher in the cancer
group (82.1%; 58.3–106.1 days) than in the non-
cancer group (50.5%; 98.5–148.4 days) (Fig 4).
3.5 Oral morphine equivalent dose
The mean OMEQ for the total patient population over
the study period was 88.9 ± 8.7 mg/day and was
slightly higher for patients with cancer diagnoses
(105.9 ± 6.1 mg/day) than with non-cancer diagnoses
(86.0 ± 8.7 mg/day) (Fig. 5).
Of the four dose ranks of annual OMEQ dose per
patient day (Fig. 4), there was a higher proportion of
patients in the low dose rank (≤50 mg/day) in both the
non-cancer (50.3%) and the cancer (39.9%) groups,
followed by the dose ranks of 51–100 mg/day
(26.2% vs. 28.7%), 101–200 mg/day (15.1% vs.
19.2%) and >200 mg/day (8.25% vs. 12.1%). The
greatest increase in the number of patients over time
was in the lowest OMEQ dose rank for both the non-
cancer (606.2%) and the cancer (309.1%) groups
compared with the increases in other dose ranks,
that is, 51–100 mg/day (397.3% vs. 217.0%), 101–
200 mg/day (430.6% vs. 206.1%) and >200 mg/day
(447.8% vs. 252.5%) during the 11-year study period
(Fig. 4).
The highest proportion of dose in the low OMEQ
rank (≤50 mg/day) was contributed by morphine
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(45.2% vs. 72.1%), followed by buprenorphine
(37.1% vs. 12.5%), oxycodone (11.1% vs. 10.4%)
and fentanyl (6.6% vs. 4.9%) in non-cancer and
cancer groups, respectively. However, there was a
decreasing trend in the proportion of OMEQ dose con-
tributed by morphine over time across the four dose
ranks (Fig. 6). In contrast, the proportion of OMEQ
dose contributed by oxycodone increased over time in
all dose ranks.
In both study groups, the proportion of OMEQ con-
tributed by buprenorphine also increased over time in
all dose ranks, but predominantly this increase was in
the low OMEQ rank (≤50 mg/day) from 30.9% to
45.9% in the non-cancer group versus 3.9% to 19.8%
in the cancer group. The proportion of OMEQ contrib-
uted by fentanyl increased over time in the low OMEQ
rank (0.5–8.9% in the non-cancer vs. 1.5–7.9% in
cancer groups), but the proportions remained consis-
tent in other dose ranks in both study groups. These
trend changes in the proportions of OMEQ dose con-
tributed by different opioids over time were consistent
in both the cancer and the non-cancer patient groups.
4. Discussion
Consistent with opioid utilization in other European
countries (Hamunen et al., 2009; Fredheim et al.,
2010), this cross-sectional study found a huge increase
in strong opioid prescribing in a UK primary care
setting from 2000 to 2010, and the majority was pre-
scribed for non-cancer patients. A greater increase in
prescriptions than the number of patients exposed to
strong opioids, and increasing days of supply were also
consistently found across the 11-year period.
Compared with recent national dispensing data
(National Health Service. The Information Centre for
Health and Social Care, 2013), this study included
about 10% of strong opioid prescriptions in the United
Kingdom, which coincides with approximately 8% of
the UK population registered with CPRD (Lawrenson
et al., 1999). Despite adopting an arbitrary definition
to categorize patients with cancer or non-cancer diag-
nosis, this may have possibly under- or overestimated
the strong opioid prescriptions for non-cancer
(87.8%) and cancer pain (12.1%). However, the
results are comparable with a Danish study that found
9.5% of opioid prescriptions were issued for cancer
pain by general practitioners over a 12-month period
(Clausen, 1997). The concordance of recording cancer
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diagnoses in CPRD with national cancer registries is
relatively high (83.3%) (Boggon et al., 2013) and the
most common primary tumour sites in 29,825 patients
registered with CPRD who died between 2000 and
2008 were lung (34.2%), colorectal (19.9%), female
breast (21.6%) and prostate (19.1%) (Higginson and
Gao, 2012).
The predominant strong opioid users were between
66 and 80 years old in both the non-cancer and the
cancer patient groups. This is perhaps unsurprising as
older people report more pain conditions and are more
likely to be prescribed with opioids than younger
population (Parsells Kelly et al., 2008; Fredheim et al.,
2010). However, the increase in prescribing for the
youngest age group (<40 years) and consequent
potential increased exposure is concerning given the
increased understanding of harms associated with
long-term opioid use.
Previous research has also suggested that female
patients are more likely to report a range of chronic
pain conditions (Unruh, 1996), and more frequently
report severe pain, longer lasting pain and anatomi-
cally diffuse pain than male patients (Hurley and
Adams, 2008). This study also demonstrated clear
variation in gender; the majority of non-cancer strong
opioid users were female (62.4%) but the proportions
of female and male were similar in the cancer group.
This finding is consistent with the results of a Norwe-
gian study from 2004 to 2007 that evaluated opioid
dispensing data with reimbursement codes for identi-
fying cancer that reported a higher proportion of
female patients (57%) in a non-cancer group and a
similar proportion between female (49%) and male
patients in the cancer group (Fredheim et al., 2010).
This study reported both DDD and OMEQ dose to
measure the utilization of strong opioids. DDD per
1000 inhabitants per day reflects the proportion of the
population in primary care, on average, that receive
a particular drug daily, and this measure allows
cross-nation comparison of drug exposure (WHO
International Working Group for Drug Statistics
Methodology. WHO Collaborating Centre for
Drug Statistics Methodology. WHO Collaborating
Centre for Drug Utilization Research and Clinical
Pharmacological Services, 2003). Of the four strong
opioids, this study found a higher proportion of
patients exposed to morphine, but the increase of pro-
portion was greater for oxycodone, buprenorphine
and fentanyl in both non-cancer and cancer groups
over time. A similar pattern was also observed in an
opioid utilization study comparing across five Nordic
countries (Denmark, Norway, Sweden, Finland and
Iceland) (Hamunen et al., 2009).
Hamunen et al. (2009) evaluated the trends
of opioid consumption presented as DDDs/1000
inhabitants/day for patients (with non-cancer or
cancer conditions) in both hospital and primary care
settings from 2002 to 2006 using national reimburse-
ment databases of the five Nordic countries, and
found morphine consumption was stable or slightly
decreased in all countries. However, fentanyl con-
sumption increased in Denmark, Finland and Sweden,
oxycodone consumption dramatically increased in
all countries except Iceland, and buprenorphine
consumption also increased in all countries (Hamunen
et al., 2009). Increasingly, oxycodone is considered the
first choice opioid analgesic for opioid-naive patients
by both hospital physicians and general practitioners
(Poulsen et al., 2013).
Although DDD is considered to be the best available
tool of measuring drug utilization in cross-nation com-
parison studies, it does not consider equianalgesic
doses of different opioid (Hamunen et al., 2008).
Therefore, this study also considered OMEQ to
measure opioid use and found that the majority of
patients in both non-cancer and cancer groups were
prescribed a low daily OMEQ dose, and the number
and proportion of patients in the low dose rank
increased over time. In the non-cancer group, the
proportion of dose calculation contributed by
buprenorphine in low OMEQ dose rank dramatically
increased after 2005, and this trend coincides with the
launch of 7-day patch formulation in 2005.
With the increase in both numbers of strong opioid
users and prescriptions, the numbers of patients who
were prescribed with strong opioids in the higher dose
ranks also increased, which raises drug safety con-
cerns. Other research have suggested that patients
receiving higher dose regimens are more likely to
deviate from medically prescribed use (e.g., increasing
dose above the prescribed levels, using opioids that
were not prescribed or using other substances that
influence overdose risks) (Dunn et al., 2010) and
several studies conducted in the United States have
also demonstrated that higher opioid doses were asso-
ciated with increased risk of opioid overdose death
(Dunn et al., 2010; Bohnert et al., 2011).
Although morphine was the main contributor to the
higher OMEQ dose ranks (51–100, 101–200 and
>200 mg/day), the proportion decreased throughout
the study period. In contrast, the proportions contrib-
uted by oxycodone and buprenorphine increased in
higher dose ranks over time. The increasing contribu-
tion of oxycodone to higher opioid doses has also been
found in a nested case–control study conducted in
Canada (Gomes et al., 2011), which reported a direct
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association between opioid dose and opioid-related
mortality, in which high (200–400 mg/day) and very
high (>400 mg/day) daily doses were associated with
double the all-cause mortality but five to six times of
the opioid-related mortality rate. Oxycodone and, to a
lesser extent, fentanyl were the main contributors to
doses exceeding 200 mg morphine equivalent per day.
The study took a cross-sectional trend design to
evaluate the trends of strong opioid utilization over 11
years using a representative and well-recorded
primary care dataset (Walley and Mantgani, 1997),
which has been previously used for research on anal-
gesics and pain (Hall et al., 2006; Gao et al., 2011) to
avoid recall bias, and included all users of the four
strong opioids to avoid selection bias. Sensitivity
analyses exploring the management of missing data
found no significant influence of the imputation pro-
cedure on dose calculation. However, as this study
only included the prescribing data of strong opioids, it
may overestimate the actual consumption in primary
care. However, the publicly available summary of
primary care dispensing data for all of England and
Wales showed a trend similar to this study (National
Health Service. The Information Centre for Health and
Social Care, 2013).
In contrast to the traditional cohort study approach,
this study took a simplistic definition to stratify the
cancer and non-cancer groups after a first cancer diag-
nosis was recorded for a patient, thus could possibly
underestimate the utilization of strong opioids for
non-cancer conditions. Without longitudinal follow-
up for individual patient’s diseases and their persis-
tence of strong opioid utilization, it was not possible
to differentiate whether the strong opioids were
prescribed for acute or chronic pain conditions, and
whether the prescribed opioids were taken by
patients. Likewise, we were not able to judge whether
the change of utilization trends indicate improvement
in pain management as clinical outcomes were not
evaluated.
5. Conclusions
To our knowledge, this is the first large-scale observa-
tional study describing the trends in strong opioid
prescribing within UK primary care settings over an
11-year study period that stratified patients into
cancer and non-cancer groups. Although the defini-
tions used to stratify the non-cancer and cancer
groups may result in overestimation of strong opioids
prescribed for cancer pain in primary care, this study
found an escalating of strong opioid prescribing in the
UK primary care setting between 2000 and 2010, pre-
dominately prescribed for non-cancer patients. Similar
patterns of opioid utilization have been reported
across European countries, and the decrease of mor-
phine seems to be complemented by an increase of
oxycodone, fentanyl and buprenorphine.
To evaluate the appropriateness of opioid utilization
(over- or under-prescribing), further well-designed
longitudinal studies are needed to evaluate the effec-
tiveness and safety of long-term opioid therapy pain
management, particularly the dose-related risk and
benefit profiles in elderly patients with non-cancer
pain conditions. Being equally effective and cheaper
than other opioid analgesics, morphine has long been
recommended as the gold standard for pain therapy
(Bekkering et al., 2011). However, with increasing
availability of opioids in novel formulations (such as
transdermal fentanyl and buprenorphine) and better
efficacy or safety profiles (Bekkering et al., 2011),
clinical guidance on opioid analgesics need to consider
not only robust clinical and economic evidence but
also other factors (such as convenience of dosing,
doctor/patient preferences, anticipated adverse effects)
in determining the choice of opioid.
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